文献速递睡眠呼吸障碍

阿莫达非尼对睡眠呼吸暂停驾驶任务表现与减重的影响:随机试验

Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究为安慰剂对照双盲随机试验,纳入拒绝标准治疗且日间嗜睡的成人超重OSA患者,阿莫达非尼联合饮食减重6个月并随访1年。结果显示阿莫达非尼3个月改善驾驶任务表现,但未达6个月主要终点;6个月体脂减少较安慰剂多2.4 kg,其他次要结局未显著改善。

要点

  • 阿莫达非尼未改善6个月主要终点驾驶任务表现。
  • 3个月时驾驶任务表现有改善,但非主要时间点。
  • 6个月体脂减少较安慰剂多2.4 kg,需专门试验验证。

核心结论

  • 阿莫达非尼未改善6个月主要终点驾驶任务表现。
  • 阿莫达非尼可能作为拒绝常规治疗OSA患者减重的辅助,但需专门设计、足够把握度的临床试验直接验证。

研究设计与样本

  • 安慰剂对照、双盲、随机试验,阿莫达非尼与安慰剂每日服用6个月。
  • 患者同时随机接受两种饮食之一6个月,随访至1年。
  • 研究对象为拒绝标准治疗且日间嗜睡的成人超重OSA患者。

主要发现

  • 主要终点为6个月时90分钟下午驾驶任务最后30分钟转向偏差变化。
  • 3个月时阿莫达非尼较安慰剂改善驾驶任务表现12.9 cm(95%CI 4.1-21.7;P=0.004)。
  • 6个月主要时间点驾驶任务表现差异为5.5 cm(95%CI -3.3至14.3;P=0.223)。
  • 6个月时阿莫达非尼组体脂较安慰剂组多减少2.4 kg(95%CI 0.9-4.0;P=0.002)。
  • Epworth嗜睡量表、睡眠功能结局问卷等其他次要结局未显著改善。

关键数值与推荐

  • 主要终点:6个月时90分钟下午驾驶任务最后30分钟转向偏差变化(AusED)。
  • 次要结局包括Epworth嗜睡量表、睡眠功能结局问卷及双能X线吸收法测定的体脂质量。

临床怎么用

  • 对拒绝标准治疗的OSA患者,阿莫达非尼不宜以改善6个月驾驶表现为目的使用。
  • 阿莫达非尼联合减重可能有助于减少体脂,但需专门试验验证后再考虑辅助应用。

局限性

  • 阿莫达非尼仅在3个月而非6个月主要时间点改善驾驶任务表现。
  • 其他次要结局未显著改善。
  • 作者指出阿莫达非尼作为减重辅助的潜在作用需专门设计、足够把握度的临床试验直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Patients with obstructive sleep apnea (OSA) unable to tolerate standard treatments have few alternatives. They may benefit from weight loss, but the major symptom of daytime performance impairment may remain during weight loss programs. OBJECTIVES: We hypothesized that wakefulness-promoter armodafinil would improve driving task performance over placebo in patients undergoing weight loss. METHODS: This was a placebo-controlled, double-blind, randomized trial of armodafinil versus placebo daily for 6 months in patients who were also randomized to one of two diets for 6 months with follow-up at 1 year in overweight, adult, patients with OSA who had rejected standard treatment and suffered daytime sleepiness. MEASUREMENTS AND MAIN RESULTS: Primary outcome was change in steering deviation in the final 30 minutes of a 90-minute afternoon driving task (AusED) at 6 months. Secondary outcomes were Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, and fat mass measured by dual-emission X-ray absorptiometry. Armodafinil improved driving task performance over placebo at 3 months (12.9 cm; 95% confidence interval, 4.1-21.7; P = 0.004), but not the primary time point of 6 months (5.5 cm; 95% confidence interval, -3.3 to 14.3; P = 0.223). Patients on armodafinil lost 2.4 kg more fat than those on placebo at 6 months (95% confidence interval, 0.9-4.0; P = 0.002). Other secondary outcomes were not significantly improved. CONCLUSIONS: Armodafinil did not improve driving task performance at the primary endpoint of 6 months. Armodafinil might be a useful adjunctive to weight loss in patients with OSA rejecting conventional treatments but this needs to be directly tested in a specifically designed, properly powered clinical trial. Clinical trial registered with Australian and New Zealand Clinical Trials Registry (ACTRN 12611000847910).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Chapman JL, Cayanan EA, Hoyos CM, et al. Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial. Am J Respir Crit Care Med. 2018. PMID: 29775087. doi:10.1164/rccm.201712-2439OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。